These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33081372)

  • 41. Bradykinin receptor 1 activation exacerbates experimental focal and segmental glomerulosclerosis.
    Pereira RL; Buscariollo BN; Corrêa-Costa M; Semedo P; Oliveira CD; Reis VO; Maquigussa E; Araújo RC; Braga TT; Soares MF; Moura IC; Malheiros DM; Filho AP; Keller AC; Câmara NO
    Kidney Int; 2011 Jun; 79(11):1217-27. PubMed ID: 21412216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
    Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
    Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
    Pandey P; Roy KK; Doerksen RJ
    J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor.
    Miao Y; Goldfeld DA; Moo EV; Sexton PM; Christopoulos A; McCammon JA; Valant C
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5675-84. PubMed ID: 27601651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aspartic acid scaffold in bradykinin B1 antagonists.
    Huszár J; Timár Z; Bogár F; Penke B; Kiss R; Szalai KK; Schmidt E; Papp A; Keseru G
    J Pept Sci; 2009 Jun; 15(6):423-34. PubMed ID: 19378355
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Involvement of prostaglandin E(2) derived from enteric glial cells in the action of bradykinin in cultured rat myenteric neurons.
    Murakami M; Ohta T; Otsuguro K; Ito S
    Neuroscience; 2007 Mar; 145(2):642-53. PubMed ID: 17275193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain.
    Campos MM; Leal PC; Yunes RA; Calixto JB
    Trends Pharmacol Sci; 2006 Dec; 27(12):646-51. PubMed ID: 17056130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blockade of the kinin B1 receptor affects the cytokine/chemokine profile in rat brain subjected to autoimmune encephalomyelitis.
    Podsiadło K; Sulkowski G; Dąbrowska-Bouta B; Strużyńska L
    Inflammopharmacology; 2017 Aug; 25(4):459-469. PubMed ID: 28160128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allosteric modulation in monomers and oligomers of a G protein-coupled receptor.
    Shivnaraine RV; Kelly B; Sankar KS; Redka DS; Han YR; Huang F; Elmslie G; Pinto D; Li Y; Rocheleau JV; Gradinaru CC; Ellis J; Wells JW
    Elife; 2016 May; 5():. PubMed ID: 27151542
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
    Schmitz J; van der Mey D; Bermudez M; Klöckner J; Schrage R; Kostenis E; Tränkle C; Wolber G; Mohr K; Holzgrabe U
    J Med Chem; 2014 Aug; 57(15):6739-50. PubMed ID: 25051097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Homology modeling, docking, and molecular dynamics simulation of the receptor GALR2 and its interactions with galanin and a positive allosteric modulator.
    Hui WQ; Cheng Q; Liu TY; Ouyang Q
    J Mol Model; 2016 Apr; 22(4):90. PubMed ID: 27021209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TRR469, a potent A(1) adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice.
    Vincenzi F; Targa M; Romagnoli R; Merighi S; Gessi S; Baraldi PG; Borea PA; Varani K
    Neuropharmacology; 2014 Jun; 81():6-14. PubMed ID: 24486382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.
    Kuduk SD; Di Marco CN; Chang RK; Wood MR; Schirripa KM; Kim JJ; Wai JM; DiPardo RM; Murphy KL; Ransom RW; Harrell CM; Reiss DR; Holahan MA; Cook J; Hess JF; Sain N; Urban MO; Tang C; Prueksaritanont T; Pettibone DJ; Bock MG
    J Med Chem; 2007 Jan; 50(2):272-82. PubMed ID: 17228869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema.
    Austinat M; Braeuninger S; Pesquero JB; Brede M; Bader M; Stoll G; Renné T; Kleinschnitz C
    Stroke; 2009 Jan; 40(1):285-93. PubMed ID: 18988906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benzodiazepines as potent and selective bradykinin B1 antagonists.
    Wood MR; Kim JJ; Han W; Dorsey BD; Homnick CF; DiPardo RM; Kuduk SD; MacNeil T; Murphy KL; Lis EV; Ransom RW; Stump GL; Lynch JJ; O'Malley SS; Miller PJ; Chen TB; Harrell CM; Chang RS; Sandhu P; Ellis JD; Bondiskey PJ; Pettibone DJ; Freidinger RM; Bock MG
    J Med Chem; 2003 May; 46(10):1803-6. PubMed ID: 12723943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of the cytosolic carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction.
    Faussner A; Proud D; Towns M; Bathon JM
    J Biol Chem; 1998 Jan; 273(5):2617-23. PubMed ID: 9446564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A possible common pharmacophore in the non-peptide antagonists of the bradykinin B1 receptor.
    Marceau F
    Trends Pharmacol Sci; 2005 Mar; 26(3):116-8. PubMed ID: 15749155
    [No Abstract]   [Full Text] [Related]  

  • 58. The action of a negative allosteric modulator at the dopamine D
    Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
    SarathKumar B; Lakshmi BS
    J Mol Model; 2019 Aug; 25(9):272. PubMed ID: 31451955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide-treated rats.
    Belichard P; Luccarini JM; Defrêne E; Faye P; Franck RM; Duclos H; Paquet JL; Pruneau D
    Br J Pharmacol; 1999 Sep; 128(1):213-9. PubMed ID: 10498854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.